510(K) SUMMARY/STATEMENT FINAL RULE PROTECTS TRADE SECRET DATA FROM PUBLIC DISCLOSURE; ACCURACY CERTIFICATION REQUIREMENTS CLARIFIED BY FDA
This article was originally published in The Gray Sheet
Executive Summary
Provisions in FDA's final rule on 510(k) premarket notification summaries and 510(k) statements will give manufacturers protection from the release of confidential information, particularly data on the technological characteristics of a product. The rule, published in the Dec. 14 Federal Register, states that FDA "does not intend that [510(k)] submitters include trade secret or confidential commercial information in the 510(k) summaries, which Congress expressly intended for public disclosure."
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.